- Papers in database
- 5
- Years active
- 2023 – 2026
- Health outcomes studied
- 1
Health Outcomes Studied
Papers (5)
- 2026Clinical Safety and Tolerability of <i>Bifidobacterium bifidum</i> BBi32: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial With Genomic and In Vitro Corroboration.10.1002/fsn3.71420
- 2026Gut microbiota and immune regulation by Lactobacillus delbrueckii subsp. bulgaricus LB42: From preclinical safety assessment to clinical evidence.10.1016/j.fct.2025.115851
- 2026Probiotic Supplementation With <i>Bifidobacterium longum</i> Subsp. <i>Longum</i> BL21 Improves Glycemic Control and Modulates Gut Microbiota in Type 2 Diabetes: A Randomized Controlled Trial.10.1002/fsn3.71437
- 2024Extensive genomic characterization, pre-clinical probiotic evaluation, and safety analysis of Bifidobacterium longum subsp. longum BL21 isolated from infant feces.10.1016/j.micpath.2024.107100
- 2023Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study10.3389/fnut.2023.1105694